Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECIDING: Disitamab Vedotin + Toripalimab + RT for MIBC
NCT07142200Phase 2Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Sep 2025
- Primary completion
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin, toripalimab in muscle-invasive bladder cancer (MIBC), sponsored by Renji Hospital. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
disitamab vedotintoripalimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07142200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07142200.